← Back

Innovate Corp

INNOVATE Corp. operates through subsidiaries in infrastructure, life sciences, and spectrum areas in the United States. Its Infrastructure segment provides industrial construction, structural steel, and facility maintenance services, including fabrication of steel components, water pipes, and tanks, as well as digital engineering and heavy equipment installation. The Life Sciences segment develops products for early knee osteoarthritis and skin technologies, while the Spectrum segment operates over-the-air broadcasting stations. Formerly HC2 Holdings, Inc., it changed its name to INNOVATE Corp. in September 2021, was incorporated in 1994, and is headquartered in New York, New York.

Price · split & dividend adjusted
News & notes moving VATE
VATE

IES Holdings to Acquire DBM Global for $650 Million

IES Holdings, Inc. has announced a definitive agreement to acquire DBM Global from INNOVATE Corp. for approximately $650 million in combined cash and stock, with total consideration reaching $685 million including minority interest buyouts and tax election payments. IES Holdings reported stellar fiscal Q3 2026 results, with revenue surging 40% year-over-year to $1.24 billion and net income nearly doubling to $153.0 million, while ending the quarter debt-free with $77.3 million in cash and $310.6 million in marketable securities. The company's backlog reached a record $4.5 billion, and its board authorized a two-for-one stock split. INNOVATE Corp.'s Q2 2026 results showed consolidated revenue climbing 74.2% to $421.6 million, but DBM Global accounted for $414.0 million of that revenue and $48.7 million of total Adjusted EBITDA, highlighting its dependence on the unit being sold. The $545 million cash proceeds from the sale will allow INNOVATE to de-lever its balance sheet, but its remaining operations, Spectrum and Life Sciences, remain unprofitable or cash-starved. Hedge fund data shows stronger conviction in IES Holdings, with ownership increasing from 34 to 39 funds, while INNOVATE saw a rise from five to eight funds.
Insider Monkey·21dRead more →
VATE

INNOVATE Q2 Revenue Surges 74% to $421.6 Million on Record Infrastructure Performance

INNOVATE Corp. reported second-quarter 2026 revenue of $421.6 million, a 74.2% increase from a year earlier, driven by record results in its Infrastructure segment. Net income attributable to common and participating preferred stockholders reached $10.4 million, or $0.71 per fully diluted share, compared with a net loss of $22 million, or $1.67 per share, in the prior-year quarter. Consolidated adjusted EBITDA rose to $46.3 million from $15.7 million. The Infrastructure segment, led by DBM Global, posted record quarterly revenue of $414 million and adjusted EBITDA of $48.7 million, with reported backlog growing to $1.9 billion and adjusted backlog reaching $2.7 billion. Broadcasting entered a definitive agreement for CONX Corp. to acquire a controlling interest of about 75%, while Life Sciences revenue fell 31.3% to $2.2 million amid weaker R2 sales and liquidity constraints.
MarketBeat·40dRead more →
VATE2

INNOVATE’s DBM Global to Pay $12 Million Cash Dividend

INNOVATE Corp. announced that its operating subsidiary DBM Global Inc. will pay a cash dividend of approximately $12 million, or $3.12 per share, on August 3, 2026 to DBMG stockholders of record as of July 20, 2026. As the largest stockholder of DBMG, INNOVATE expects to receive approximately $11 million of the total payout. INNOVATE’s individual stockholders are not eligible to receive the cash dividend.
GlobeNewswire·72dRead more →
Semiconductors2

Zacks highlights Applied Materials, Mastercard, AbbVie, INNOVATE, and BranchOut in latest analyst reports

Zacks Equity Research released new analyst reports on 16 major stocks, including Applied Materials, Mastercard, and AbbVie, along with micro-cap companies INNOVATE and BranchOut Food. Applied Materials benefits from AI-driven demand and record revenue, though faces China export rule risks. Mastercard sees steady payment network growth but rising expenses and geopolitical headwinds. AbbVie navigates Humira's loss of exclusivity with strong immunology launches Skyrizi and Rinvoq, while expanding its neuroscience portfolio. INNOVATE's investment case is anchored by DBMG's infrastructure exposure, but a highly leveraged balance sheet tempers the outlook. BranchOut Food shows improving revenue visibility through European private-label expansion and a strengthening retail pipeline.
Zacks Investment Research·75dRead more →